Does the media prefer ZLAB or CBIO?

In the previous week, Crescent Biopharma had 27 more articles in the media than Zai Lab. MarketBeat recorded 29 mentions for Crescent Biopharma and 2 mentions for Zai Lab. Crescent Biopharma's average media sentiment score of 0.34 beat Zai Lab's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or CBIO more profitable?

Immunome's return on equity of -50.56% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Crescent Biopharma N/A -101.50% -86.86%

Does the media prefer IMNM or CBIO?

In the previous week, Crescent Biopharma had 25 more articles in the media than Immunome. MarketBeat recorded 29 mentions for Crescent Biopharma and 4 mentions for Immunome. Immunome's average media sentiment score of 0.56 beat Crescent Biopharma's score of 0.34 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CBIO or CDNA?

CareDx has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Crescent Biopharma $10.84M 48.62 -$153.94M -$6.72 N/A CareDx $458.09M 6.13 -$21.35M $2.07 26.24

Does the media favor CBIO or CDNA?

In the previous week, Crescent Biopharma had 23 more articles in the media than CareDx. MarketBeat recorded 29 mentions for Crescent Biopharma and 6 mentions for CareDx. CareDx's average media sentiment score of 0.69 beat Crescent Biopharma's score of 0.34 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CBIO or NAMS?

In the previous week, Crescent Biopharma had 18 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 29 mentions for Crescent Biopharma and 11 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.55 beat Crescent Biopharma's score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral NewAmsterdam Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NRIX or CBIO?

In the previous week, Crescent Biopharma had 28 more articles in the media than Nurix Therapeutics. MarketBeat recorded 29 mentions for Crescent Biopharma and 1 mentions for Nurix Therapeutics. Crescent Biopharma's average media sentiment score of 0.34 beat Nurix Therapeutics' score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Crescent Biopharma (CBIO) Competitors

$14.19 -2.25 (-13.69%)

Closing price 04:00 PM Eastern

Extended Trading

$14.06 -0.13 (-0.88%)

As of 07:30 PM Eastern

Compare

CBIO vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

Should you buy Crescent Biopharma stock or one of its competitors? Crescent Biopharma's main competitors and comparable companies include Zai Lab (ZLAB), Immunome (IMNM), CareDx (CDNA), NewAmsterdam Pharma (NAMS), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Zai Lab?

Zai Lab (NASDAQ:ZLAB) and Crescent Biopharma (NASDAQ:CBIO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Crescent Biopharma has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Crescent Biopharma	N/A	-101.50%	-86.86%

Zai Lab has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Crescent Biopharma has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$449.61M	6.69	-$175.54M	-$1.71	N/A
Crescent Biopharma	$10.84M	48.62	-$153.94M	-$6.72	N/A

Zai Lab currently has a consensus target price of $37.25, indicating a potential upside of 40.89%. Crescent Biopharma has a consensus target price of $29.60, indicating a potential upside of 108.60%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

In the previous week, Crescent Biopharma had 27 more articles in the media than Zai Lab. MarketBeat recorded 29 mentions for Crescent Biopharma and 2 mentions for Zai Lab. Crescent Biopharma's average media sentiment score of 0.34 beat Zai Lab's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Crescent Biopharma beats Zai Lab on 12 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Immunome?

Immunome (NASDAQ:IMNM) and Crescent Biopharma (NASDAQ:CBIO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

44.6% of Immunome shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 7.2% of Immunome shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immunome presently has a consensus price target of $35.18, suggesting a potential upside of 45.14%. Crescent Biopharma has a consensus price target of $29.60, suggesting a potential upside of 108.60%. Given Crescent Biopharma's higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Immunome has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

In the previous week, Crescent Biopharma had 25 more articles in the media than Immunome. MarketBeat recorded 29 mentions for Crescent Biopharma and 4 mentions for Immunome. Immunome's average media sentiment score of 0.56 beat Crescent Biopharma's score of 0.34 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	396.71	-$212.39M	-$2.53	N/A
Crescent Biopharma	$10.84M	48.62	-$153.94M	-$6.72	N/A

Immunome's return on equity of -50.56% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Crescent Biopharma	N/A	-101.50%	-86.86%

Summary

Immunome and Crescent Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to CareDx?

Crescent Biopharma (NASDAQ:CBIO) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

CareDx has a net margin of 24.23% compared to Crescent Biopharma's net margin of 0.00%. CareDx's return on equity of 2.87% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
CareDx	24.23%	2.87%	2.17%

75.2% of Crescent Biopharma shares are held by institutional investors. 24.8% of Crescent Biopharma shares are held by insiders. Comparatively, 2.4% of CareDx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CareDx has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	48.62	-$153.94M	-$6.72	N/A
CareDx	$458.09M	6.13	-$21.35M	$2.07	26.24

Crescent Biopharma has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, CareDx has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market.

Crescent Biopharma currently has a consensus price target of $29.60, indicating a potential upside of 108.60%. CareDx has a consensus price target of $51.20, indicating a potential downside of 5.73%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
CareDx	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.63

In the previous week, Crescent Biopharma had 23 more articles in the media than CareDx. MarketBeat recorded 29 mentions for Crescent Biopharma and 6 mentions for CareDx. CareDx's average media sentiment score of 0.69 beat Crescent Biopharma's score of 0.34 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CareDx beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to NewAmsterdam Pharma?

Crescent Biopharma (NASDAQ:CBIO) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Crescent Biopharma has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-101.50%	-86.86%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

Crescent Biopharma has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	48.62	-$153.94M	-$6.72	N/A
NewAmsterdam Pharma	$22.50M	120.50	-$203.82M	-$2.16	N/A

Crescent Biopharma has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Crescent Biopharma presently has a consensus target price of $29.60, suggesting a potential upside of 108.60%. NewAmsterdam Pharma has a consensus target price of $49.73, suggesting a potential upside of 119.26%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 24.8% of Crescent Biopharma shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Crescent Biopharma had 18 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 29 mentions for Crescent Biopharma and 11 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.55 beat Crescent Biopharma's score of 0.34 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NewAmsterdam Pharma beats Crescent Biopharma on 10 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Crescent Biopharma (NASDAQ:CBIO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

In the previous week, Crescent Biopharma had 28 more articles in the media than Nurix Therapeutics. MarketBeat recorded 29 mentions for Crescent Biopharma and 1 mentions for Nurix Therapeutics. Crescent Biopharma's average media sentiment score of 0.34 beat Nurix Therapeutics' score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Crescent Biopharma has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nurix Therapeutics' return on equity of -76.09% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Crescent Biopharma	N/A	-101.50%	-86.86%

Crescent Biopharma has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	29.51	-$264.46M	-$3.45	N/A
Crescent Biopharma	$10.84M	48.62	-$153.94M	-$6.72	N/A

Nurix Therapeutics currently has a consensus price target of $34.21, indicating a potential upside of 43.28%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 108.60%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Crescent Biopharma is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Nurix Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Summary

Crescent Biopharma beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$527.02M	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	-2.11	13.95	274.58	25.69
Price / Sales	48.62	1,386.64	648.78	85.88
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	0.99	15.30	10.44	6.32
Net Income	-$153.94M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-17.40%	-0.22%	0.51%	1.35%
1 Month Performance	-17.26%	-6.06%	-3.38%	-3.68%
1 Year Performance	9.58%	34.37%	16.04%	5.56%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	3.1089 of 5 stars	$14.19 -13.7%	$29.60 +108.6%	+25.4%	$527.02M	$10.84M	N/A	44	High Trading Volume
ZLAB Zai Lab	1.8762 of 5 stars	$24.80 +0.9%	$37.25 +50.2%	-20.3%	$2.80B	$460.16M	N/A	1,784	News Coverage
IMNM Immunome	2.7041 of 5 stars	$23.95 -2.4%	$34.64 +44.6%	+163.6%	$2.79B	$6.94M	N/A	177	Analyst Forecast
CDNA CareDx	2.7575 of 5 stars	$52.64 +0.5%	$51.20 -2.7%	+276.9%	$2.71B	$379.80M	25.43	765
NAMS NewAmsterdam Pharma	3.3464 of 5 stars	$21.16 -5.4%	$49.73 +135.0%	-13.8%	$2.67B	$22.50M	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

How does Crescent Biopharma compare to Zai Lab?

Summary

How does Crescent Biopharma compare to Immunome?

Summary

How does Crescent Biopharma compare to CareDx?

Summary

How does Crescent Biopharma compare to NewAmsterdam Pharma?

Summary

How does Crescent Biopharma compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. ZLAB, IMNM, CDNA, NAMS, and NRIX

How does Crescent Biopharma compare to Zai Lab?

Is ZLAB or CBIO more profitable?

Which has more risk and volatility, ZLAB or CBIO?

Which has preferable earnings & valuation, ZLAB or CBIO?

Do analysts prefer ZLAB or CBIO?

Does the media prefer ZLAB or CBIO?

Do institutionals and insiders believe in ZLAB or CBIO?

Summary

How does Crescent Biopharma compare to Immunome?

Do insiders & institutionals hold more shares of IMNM or CBIO?

Do analysts prefer IMNM or CBIO?

Which has more risk & volatility, IMNM or CBIO?

Does the media prefer IMNM or CBIO?

Which has stronger earnings & valuation, IMNM or CBIO?

Is IMNM or CBIO more profitable?

Summary

How does Crescent Biopharma compare to CareDx?

Is CBIO or CDNA more profitable?

Do insiders and institutionals have more ownership in CBIO or CDNA?

Which has preferable earnings and valuation, CBIO or CDNA?

Which has more risk & volatility, CBIO or CDNA?

Do analysts recommend CBIO or CDNA?

Does the media favor CBIO or CDNA?

Summary

How does Crescent Biopharma compare to NewAmsterdam Pharma?

Is CBIO or NAMS more profitable?

Which has better earnings & valuation, CBIO or NAMS?

Which has more risk and volatility, CBIO or NAMS?

Do analysts rate CBIO or NAMS?

Do insiders and institutionals hold more shares of CBIO or NAMS?

Does the media favor CBIO or NAMS?

Summary

How does Crescent Biopharma compare to Nurix Therapeutics?

Does the media favor NRIX or CBIO?

Do institutionals and insiders believe in NRIX or CBIO?

Is NRIX or CBIO more profitable?

Which has stronger valuation and earnings, NRIX or CBIO?

Do analysts rate NRIX or CBIO?

Which has more risk & volatility, NRIX or CBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools